Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International, Inc. reported that it was named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards, an honor given each year to a single surgical robotics company. Management noted that SS Innovations surpassed nine other established finalists, highlighting industry recognition for its SSi Mantra surgical robotic system.
The Company also shared operational milestones. As of June 22, 2026, the SSi Mantra system had been used in 11,719 multi-specialty procedures, including 612 cardiac procedures, 175 telesurgeries and 212 pediatric surgeries, and approximately 2,100 physicians had been trained on the platform across more than 170 procedure types. The SSi Mantra had received regulatory approval in 14 countries, supporting the Company’s goal of making robotic surgery more accessible globally.
SS Innovations International, Inc. entered an ATM Sales Agreement with Virtu Americas LLC to sell up to $50 million of its common stock through an at-the-market offering program. Virtu will act as exclusive sales agent or principal and receive up to 3.0% of gross proceeds from any shares sold.
The sales will be made under the company’s effective Form S-3 shelf registration statement, supported by a new prospectus supplement filed the same day. The agreement includes customary representations, covenants, indemnification and allows either party to terminate in accordance with its terms.
SS Innovations International, Inc. is offering up to $50,000,000 of common stock in an at-the-market (ATM) program under a Sales Agreement with Virtu Americas LLC dated June 18, 2026.
Sales may occur from time to time on Nasdaq or other U.S. trading venues at market prices; Virtu may act as agent or principal and is entitled to a commission of up to 3.0% of gross proceeds. The number of shares outstanding used for this offering calculation was 200,131,535 shares as of June 17, 2026. Net proceeds, if any, are intended for working capital and general corporate purposes, including global marketing, clinical trials and manufacturing capacity expansion.
SS Innovations International, Inc. furnished a June 2026 investor presentation highlighting rapid growth in its surgical robotics business. Revenue rose to $42.5M in 2025 from $20.6M in 2024, while gross margin expanded to 46.0% from 40.9%, and net loss narrowed to $8.16M from $19.15M.
The SSi Mantra robotic system has performed 11,270 multi-specialty surgeries with 210 systems installed across 186 hospitals as of May 31, 2026, with no significant safety events reported. For the quarter ended March 31, 2026, revenue was $11.1M, more than double the prior-year quarter, and gross margin reached 48.0%.
The company held $23.6M in cash and no long-term debt as of March 31, 2026, and reported insider ownership of roughly 74% of its 200.1 million shares outstanding as of June 2, 2026. The presentation also outlines ongoing global expansion, with regulatory approvals in India and multiple countries and anticipated EU CE marking in Q4 2026 and a 510(k) pathway toward potential FDA market clearance around Q4 2026–Q1 2027.
SS Innovations International, Inc. director and Asia Pacific CEO Vishwajyoti Pascual Srivastava reported an indirect disposition of common stock through a bona fide gift. An entity he controls, Matilda Pvt. Ltd., transferred 1,000,000 shares of common stock at a stated price of $0.0000 per share. After this gift transfer, Matilda Pvt. Ltd. continues to hold 3,000,000 shares of SS Innovations International common stock indirectly for Srivastava. This is a non-market, non-cash transaction classified as a gift rather than a sale or purchase.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported a bona fide gift of 1,000,000 shares of common stock held indirectly through Sushruta Pvt. Ltd. The transaction carried a price of $0.00 per share. After the gift, 108,564,261 shares are reported as indirectly owned through Sushruta Pvt. Ltd., reflecting a large remaining position.
SS Innovations International, Inc. reported a major technical milestone: a robot-assisted heart procedure using its SSi Mantra surgical robotic system was successfully performed across approximately 12,500 miles (20,000 kilometers) of fiber network distance between Guyana and India, described as the world’s longest-distance robotic telesurgery.
The procedure used the optional SSi MantrAsana tele-surgeon console, operated remotely by CEO and cardiac surgeon Dr. Sudhir Srivastava, with the patient-side setup in Indore, India and network latency of 290-300 milliseconds. To date, 22 cardiac telesurgeries and 173 total telesurgeries have been completed using SSi Mantra, which the company states is the only system globally used for robotic cardiac telesurgery.
SSi Mantra has regulatory approval in 14 countries, including India, Guyana, Colombia, Kenya, and the United Arab Emirates, and has been clinically validated in India in more than 170 different types of surgical procedures. The company positions its platform as a modular, multi-arm, 3D 4K-capable robotic system designed to make robotic surgery more affordable and widely accessible.
SS Innovations International, Inc. insider Barry F. Cohen, who serves as COO - Americas and a director, reported a bona fide gift of 25,000 shares of Common Stock. The transaction carried a stated price of $0.00 per share. After the gift, he directly holds 7,755,088 shares.
SS Innovations International, Inc. reported a senior leadership change. On May 18, 2026, Milan Rao informed the company he will step down as Global Chief Operating Officer and Chief Financial Officer, effective May 25, 2026.
The company stated that it has begun a search process to identify and recruit a permanent successor for the Chief Financial Officer role. No additional details about interim arrangements or reasons for the departure are provided in this report.
SS Innovations International, Inc. files a shelf prospectus to register up to $150,000,000 of securities and to permit resale of up to 5,016,500 shares of common stock by selling shareholders.
The prospectus registers multiple securities types (common stock, preferred, warrants, rights, units, debt) and specifically covers 5,016,500 Shares comprised of shares sold in a March 6, 2026 private placement, and shares issuable upon exercise of RCP Warrants (41,667 shares, $3.45 exercise) and HCW Warrants (500,000 shares, $8.89 exercise). The company will receive proceeds only if those warrants are exercised.
The filing describes the SSi Mantra surgical robotic system, regulatory filings including a 510(k) submission to the FDA, an installed base of 194 systems as of March 31, 2026, and cumulative use in 9,744 procedures. The prospectus discloses concentrated control by Dr. Sudhir Srivastava (approx. 55.84% beneficial ownership) and material risk factors including continued losses, regulatory and manufacturing risks, and the need for additional financing.